Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction

Urologic Oncology

Volumn 4, Issue 4-5, 1998, Pages 121-129

  Akaza, H ^a   Kurth, K H ^b   Williams, R ^c   Hinotsu, S ^d   Jewett, M A S ^e   Naito, K ^f   Okada, K ^g   Schellhammer, P F ^h   Van Velthoven, R F ⁱ   Witjes, J A ^j  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e Yamaguchi Univ School of Medicine ^*  (Canada)

^f YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF FUKUI   (Japan)

^h Eastern Virginia School of Medicine   (United States)

ⁱ JULES BORDET INSTITUTE   (Belgium)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BIOLACTIS; BROPIRIMINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN C; THIOTEPA; UNCLASSIFIED DRUG;

ANIMAL MODEL; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; LACTOBACILLUS CASEI; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; URINARY TRACT CANCER;

EID: 0344416979     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(99)00015-0     Document Type: Conference Paper

References (65)

1. [1] Aso Y, Anderson L, Soloway M, et al. Prognostic factors in superficial bladder cancer. In: Denis L, Niijima T, Prout G Jr, Schroder FH, editors. Developments in Bladder Cancer. New York: A.R. Liss, 1986. pp. 211-22.
2. [2] Aso Y, Bouffioux C, Flanigan H, et al. Prognostic factors in Ta, T1 (superficial) bladder cancer. In: Niijima T, Aso Y, Koontz W, Prout G, Jr, Denis L, editors. Consensus Development in Clinical Bladder Cancer Research. Paris: Scientific Communication International Ltd., 1993. pp. 176-86.
3. [3] Lamm DL, van der Meijden APM, Akaza H, et al. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Int J Urol 1995;2(suppl 2): 23-35.
4. [4] Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation. Influence of cauterization. Cancer 1980;46:1158-64.
5. [5] Farrow CM, Utz DC, Rife CC. Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res 1976;36:2495-501.
6. [6] Shirai T, Fradet Y, Huland H, et al. The etiology of bladder cancer. Are there any new clues or predictors of behavior? Int J Urol 1995; 2(suppl 2):64-75.
7. [7] Khuri FR, Lippman SM, Spitz MR, et al. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst 1997;89:199-211.
8. [8] Hicks RM. Multistage carcinogenesis in the urinary bladder. Br Med Bull 1980;36:39-46.
9. [9] Kawai K, Kawamata H, Kameyama S, et al. Persistence of carcinogen-altered cell population in rat urothelium which can be promoted to tumors by chronic inflammatory stimulus. Cancer Res 1994;54: 2630-2.
10. [10] Shinka T, Sawada Y, Morimoto S, Fujinaga T, Nakamura J, Ohkawa T. Clinical study on urothelial tumors of dye workers in Wakayama city. J Urol 1991;146:1504-7.
11. [11] Akaza H. Present states and problems of intravesical instillation against superficial bladder cancer. Clin Urol 1988;42:951-61.
12. [12] SAS Technical report J-117 SAS/STAT, 1993.
13. [13] Hinotsu S, Akaza H, Ohash Y, et al. Intravesical chemotherapy for prophylaxis of superficial bladder cancer after transurethral resection. A combined analysis of trials by the Urological Cancer Research Group using smoothed hazard function. (Submitted for publication.)
14. [14] Akaza H. Strategy for prevention of recurrence of superficial bladder cancer. Akt Urol 1996;27(suppl):2-4.
15. [15] Alli-El-Dein B, Nabeeh A, El-Baz M, et al. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumors: a prospective, randomized controlled study. Brit J Urol 1997;79:731-5.
16. [16] Akaza H, Hinotsu S, Aso Y, et al. Bacillus calmette-guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 1995;75:552-9.
17. [17] Fleshner NE, Herr HW, Stewart AK, et al. The national cancer data base report on bladder carcinoma. Cancer 1996;78:1505-13.
18. [18] Kurth KH, Denis L, Bouffioux C, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A(11):1840-6.
19. [19] Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Amer 1992;19:573-80.
20. [20] Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of EORTC and MRC randomized clinical trials for the prophylactic treatment of stage Ta T1 bladder cancer. J Urol 1996;156:1934-41.
21. [21] Akaza H, Koiso K, Kotake T, et al. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese urological cancer research group for adriamycin. Cancer Chem Pharmacol 1992;30:S15-20.
22. [22] Herr HW, Wartinger DD, Fair WR, et al. Bacillus calmette-guerin therapy for superficial bladder cancer: a 10-year follow up. J Urol 1992;147:1020-3.
23. [23] Lamm DL. Significant long-term patient benefit with BCG maintenance therapy: a SWOG study. J Urol 1997;157:213A,831.
24. [24] Meijden APM, Hall RR, Kurth KH, Bouffioux CH, Sylvester R. Members of EORTC Genitourinary Group. Phase II trials in Ta, T1 bladder cancer. The marker tumour concept. Brit J Urol 1996;77:634-7.
25. [25] Bono AV, Hall RR, Denis L, Lovisolo JA, Sylverster R, Members of the EORTC Genitourinary Group. Chemoresection in Ta-T1 bladder cancer. Eur Urol 1996;29:385-90.
26. [26] Akaza H, Kameyama S, Kakizoe T, et al. Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer. Jap J Urol 1992;83:183-9.
27. [27] Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bladder Cancer BCG Study Group. Bacillus calmette-guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Cancer 1995;75:552-9.
28. [28] Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local BCG therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990;144:53-8.
29. [29] Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147:1636-42.
30. [30] Bettex-Galland M, Studer UE, Walz A, Dewald B, Baggiolini M. Neurophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration. Eur Urol 1991;19:171-5.
31. [31] Böhle A, Nowc C, Ulmer AJ, et al. Detection of urinary TNF, IL 1, and IL 2 after local BCG immunothrapy for bladder carcinoma. Cytokine 1990;2:175-81.
32. [32] De Boer EC, De Jong WH, Steerenberg PA, et al. Induction of urinary IL 1, IL2, IL6, and TNF during intravesical immunotherapy with BCG in superficial bladder cancer. Cancer Immunol Immunother 1991;34:306-12.
33. [33] De Reijke ThM, De Boer EC, Kurth KH, Schamhart DHJ. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996;155:477-82.
34. [34] Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990;144:1248-50.
35. [35] Ratliff TL, Haaff EO, Catalona WJ. Interleukin 2 production during intravesical bacillus Calmette-Guérin therapy for bladder cancer. Clin Immunol Immunopathol 1986;40:375-9.
36. [36] Bohle A, Busemann E, Gerdes J, Ulmer AJ, Flad HD, Jocham D. Long-term immunobiological effects of intravesical bacillus calmette-guerin against bladder carcinoma recurrences. Develop Biol Standard 1992;77:199-209.
37. [37] De Boer EC, Schamhart DHJ, De Muinck Keizer WH, De Reijke ThM, Kurth KH. Increase of HLA-AB and HLA-DR antigen expression on urothelial cells after BCG therapy. Akt Urologie 1993;24:309-10.
38. [38] Jackson AM, Alexandroff AB, McIintyre M, Esuvaranathan K, James K, Chisholm GD. BCG immunotherapy induces ICAM-1 expression on bladder tumors. J Clin Pathol 1994;47:309-12.
39. [39] De Boer EC, Schamhart DHJ, Somogyi L, Kurth KH. Role of IL8 in onset of the BCG-induced immune response. Urol Res 1997;25: 31-4.
40. [40] De Reijke ThM, Vos PCN, De Boer EC, et al. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guérin (BCG). Urol Res 1993;21:349-52.
41. [41] De Boer EC, Bevers RFM, Kurth KH, Schamhart DHJ. Double fluorescent flow cytometric assessment of bacterial internalization and binding by epithelial cells. Cytometry 1996;25:381-7.
42. [42] Schneider B, Thannhauser A, Jocam D, et al. Specific binding of bacillus Calmette-Guérin to urothelial tumor cells in vitro. World J Urol 1994;12:337-44.
43. [43] Teppema JS, De Boer EC, Steerenberg PA, Van Der Meijden APM. Morphological aspects of the interaction of bacillus Calmette-Guérin (BCG) with urological cells in vivo and in vitro: relevance for antitumor activity? J Urol 1992;20:219-27.
44. [44] Akaza H, Iwasaki A, Ohtani M, Ikeda N, Niijima K, Toida I. Expression of antitumor response: role of attachment and viability of bacillus Calmette-Guerin to bladder cancer cells. Cancer 1993;72: 558-63.
45. [45] Ratliff TL, Palmer JO, Mac Garr JA, Brown EJ. Intravesical bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guérin. Cancer Res 1987;47:1762-6.
46. [46] Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150:1018-23.
47. [47] Ratliff TL. Mechanisms of action of intravesical BCG for bladder cancer. Progr Clin Biol Res 1989;310:107-24.
48. [48] Saint F, Patard JJ, Hoznek A, Maille P, Abbou C, Chopin D. Prognosis value of a Th1 urinary cytokine response following intravesical BCG treatment. J Urol 1997;157(suppl.):386A.
49. [49] Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19:499-508.
50. [50] De Reijke ThM, De Boer EC, Schamhart DHJ, Kurth KH. Urinary IL2 during repeated courses of intravesical BCG therapy. J Urol 1996;155:567A.
51. [51] Chin JL, Kadhim SA, Batislam E, et al. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette-Guérin (BCG) therapy in orthotopic murine bladder cancer. J Urol 1996;156:1189-93.
52. [52] Morales A, Chin J. Mycobacterial cell wall as an alternative to BCG in the treatment of carcinoma-in-situ (CIS) of bladder: an efficacy study. J Urol 1997;157(suppl):214A.
53. [53] De Boer EC, Van Brummelen D, Kurth KH, Schamhart DHJ. Chemotactic activity of bacillus Calmette-Guérin (BCG) released product(s). J Urol 1996;155(suppl):569A.
54. [54] Van Vooren JP, Zlotta AR, Drowart A, et al. Culture filtrate from bacillus Calmette-Guérin (BCG) is as effective as live BCG to enhance lymphocyte-mediated bladder tumor cell killing in man and in mice. J Urol 1997;157(suppl):383A.
55. [55] Sarosdy MF, Lowe BA, Schellhammer PF, et al. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial. Urology 1996;48(1):21-7.
56. [56] Akaza H, Shimazaki J, Tashiro K, et al. Bropirimine (U-54461 S) late phase II clinical study for carcinoma in situ of the bladder. Jpn J Cancer Chemother 1997;24:77-85.
57. [57] Akaza H, Kotake T, Shimazaki J, et al. Bropirimine, early phase II clinical study in Ta, T1 bladder cancer: direct tumor effect on marker tumor(s). Proceedings of the 12th European Association of Urology. Eur Uro 1996;30(suppl):646.
58. [58] Lamm DL, Riggs D, Shriver J, et al. Randomized double-blind comparison of high and recommended dose vitamins in superficial bladder cancer. J Urol 1993;149:283A.
59. [59] Tomita K, Akaza H, Nomoto K, et al. Influence of Lactobacillus casei on rat bladder carcinogenesis. Jpn J Urol 1994;85:655-63.
60. [60] Ohtani M, Miyanaga N, Takeshima H, et al. Inhibitory effect of Lactobacillus casei on bladder carcinogenesis in mice. J Urol 1993; 149:482A.
61. [61] Aso Y, Akaza H, Kotake T, et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 1995;27:104-9.
62. [62] Imada S, Akaza H, Ami Y, et al. Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rat. Eur Urol 1997;31:360-4.
63. [63] Kato I, Endo K, Yokokura T. Induction of antitumor activity with oral administration. Biotherapy 1992;6:1121-6.
64. [64] Tohyama K, Kobayashi Y, Kan T. Effect of lactobacilli on urinary indican excretion in gnotobiotic rats and in men. Microbial Immunol 1981;25:101-12.
65. [65] Hayatsu H, Hayatsu T. Suppressing effect of Lactobacillus casei administration on the urinary mutogenecity arising from injestion of fried ground beef in the human. Cancer Lett 1993;73:173-9.